Pharmaceutical Executive

Pharmaceutical Executive Podcast
  • 0.0（0則評分）
  • 生命科學
  • 每日更新

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

  1. Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna

    19 小時前

    Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna

    In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secures a long-term agreement in Mexico, industry leaders assess China’s evolving role in global pharma strategy, and the FDA makes a decision on Keytruda in platinum-resistant ovarian cancer.

    2 分鐘
  2. Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales

    1 天前

    Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales

    In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum Technologies close Series B financing rounds, and Iambi enters a $1 billion collaboration with Takeda to advance small-molecule programs.

    2 分鐘
  3. Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech

    2 天前

    Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech

    In a podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, and Andrew Hall, CEO of Consano Bio, discuss what effective leadership looks like in today’s volatile capital and regulatory climates for emerging biotechs. Part 1 of the conversation explores why Banta and Hall believe CEOs of these companies must act as stabilizers and translators—balancing risk with opportunity and turning complex scientific innovation into clear strategy for investors, regulators, and employees alike. Highlights of the discussion include: The EQ imperative: leading through persuasion and influence, not dictates. “It’s not about the science; it’s about the people.” The best CEOs follow a four-core formula Early stage’s mindset mix (end-game vs journey)—and the rewards of “failing fast” Why Series A’s are the “lifeblood of biotech”

    18 分鐘
  4. Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill

    2 天前

    Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill

    In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.

    2 分鐘
  5. Pharmaceutical Executive Daily: The Launch of TrumpRx

    5 天前

    Pharmaceutical Executive Daily: The Launch of TrumpRx

    In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size biotech companies

    2 分鐘
  6. Pharmaceutical Executive Daily: FDA Approves First and Only Oral Film Treatment for Erectile Dysfunction

    6 天前

    Pharmaceutical Executive Daily: FDA Approves First and Only Oral Film Treatment for Erectile Dysfunction

    In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be treated as product launch blueprints, and Veradermics completes an upsized $256 million IPO.

    2 分鐘
  7. Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026

    2月4日

    Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026

    In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders explore how pharma can tap into emerging talent hubs, and Novartis’ Q4 results highlight mounting pressure from its upcoming patent cliff.

    2 分鐘
  8. Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

    2月3日

    Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

    In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.

    2 分鐘
顯示全部 (287)

簡介

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. 

資訊

  • 創作者
    Pharmaceutical Executive Podcast
  • 活躍年代
    2018年 - 2026年
  • 集數
    287
  • 年齡分級
    兒少適宜
  • 節目網站
    Pharmaceutical Executive

你可能也會喜歡